
ACRV
Healthcare · Biotechnology · $62.1M market cap
$1.45-0.01 (-0.7%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +6.4% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Time not confirmed | -0.44 | — | — |
| Aug 12, 2026 | After the close | -0.49 | -0.43 | +12.2% |
| May 13, 2026 | After the close | -0.52 | -0.49 | +5.8% |
| Mar 19, 2026 | Time not confirmed | -0.46 | -0.49 | -7.4% |
| Nov 13, 2025 | After the close | -0.58 | -0.47 | +19.0% |
| Aug 14, 2025 | After the close | -0.58 | -0.55 | +5.2% |
| May 14, 2025 | After the close | -0.65 | -0.51 | +21.5% |
| Mar 27, 2025 | Time not confirmed | -0.77 | -0.60 | +22.1% |
| Nov 13, 2024 | Before the open | -0.59 | -0.59 | 0.0% |
| Aug 13, 2024 | Before the open | -0.57 | -0.52 | +8.8% |
| May 14, 2024 | Before the open | -0.85 | -0.73 | +14.1% |
| Mar 28, 2024 | Before the open | -0.73 | -0.86 | -17.8% |
| Nov 9, 2023 | Before the open | -0.69 | -0.66 |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature…
| +4.3% |
| Aug 11, 2023 | Before the open | -0.62 | -0.63 | -1.6% |
| May 9, 2023 | Before the open | -0.62 | -0.58 | +6.5% |
| Mar 28, 2023 | Before the open | -1.09 | -0.80 | +26.6% |
| Dec 15, 2022 | After the close | -0.92 | -5.17 | -462.0% |